Drugs that selectively kill senescent cells may benefit otherwise healthy older women but are not a "one-size-fits-all" remedy, Mayo Clinic researchers have found. Specifically, these drugs may only benefit people with a high number of senescent cells, according to findings publishing July 2 in Nature Medicine.
$5 million grant from the Agency for Healthcare Research and Quality will enhance long COVID care for underserved minority groups, community outreach, and research
The U.S. Supreme Court has blocked the Sackler family's bid for immunity from opioid-related lawsuits in a landmark decision. This ruling marks a pivotal moment in the ongoing opioid crisis, potentially reshaping how litigation against pharmaceutical companies is handled nationwide.
Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.
• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence
An expert from the Johns Hopkins Bloomberg School of Public Health is available for interviews to discuss the U.S. Supreme Court’s decision in Harrington v. Purdue Pharma.
NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.
Today, the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released the results of a survey that ADLM conducted to determine how the Food and Drug Administration’s (FDA’s) final laboratory developed tests rule will impact patient access to essential tests. The survey found that, in spite of certain tests being exempt from the rule, it will still force many laboratories, particularly those in hospitals, to discontinue critical tests, including those needed to identify prescription and illegal drug use.
CellFE Inc., a cell engineering platform company with a novel microfluidic technology for non-viral cell therapy manufacturing, announced today that life science tools executive Mike Rice has been appointed to its Board of Directors.
Medical products such as ointments or syringes reach their limits when it comes to delivering medication locally – and above all in a controlled manner over a longer period of time. Empa researchers are therefore developing polymer fibers that can deliver active ingredients precisely over the long term. These "liquid core fibers" contain drugs inside and can be processed into medical textiles.
Evaluating new novel treatment that is the first drug which can be given orally as well as IV along with antivenom to treat snakebites, especially in rural areas.
In Greek mythology, a Chimera is a creature of change, a being possessing the forms of lion, goat and dragon. But unlike the mythical creature, a new approach to fighting cancer cells throughout the body is very real and has arrived at The University of New Mexico Comprehensive Cancer Center.
A machine learning tool developed by Cedars-Sinai investigators can answer questions about genes, drugs, and biochemical pathways associated with Alzheimer’s disease and other health conditions. Their findings were published today in the journal Bioinformatics.
New research from the Indiana University Kelley School of Business explains how pharmaceutical companies were able to saturate the country with massive quantities of opioids, despite efforts by the Drug Enforcement Administration to regulate their supply.
UC San Diego School of Medicine international study shows new drug improves sleep, health in patients diagnosed with obesity and sleep apnea.
A hematologist endorses FDA approval of a new cancer drug, research shows new use for an older drug, multiple myeloma research may secure FDA approval of a new clinical endpoint, a bilingual thoracic oncologist breaks down language barriers for cancer patients, and more are in the June tip sheet.
Research published in Science Advances traced the history of human’s ability to feel cold back to the molecular underpinnings of the cold and menthol sensor TRPM8 over hundreds of millions of years. The findings could lead to non-addictive pain medications, a crucial development given the opioid crisis.
The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults.
Rutgers Health neurology, dermatology, and pharmacy researchers explain how to distinguish concerning rashes from less severe reactions.
Certain drugs used to treat urinary symptoms due to an enlarged prostate may be associated with a reduced risk of dementia with Lewy bodies, according to a study published in the June 19, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right